Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06105320
Other study ID # COGNIFOOD-Pilot
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 2023
Est. completion date April 2026

Study information

Verified date October 2023
Source Karolinska University Hospital
Contact Anne Börjesson-Hanson, MD, PhD
Phone +46-8-123 858 68
Email anne.borjesson-hanson@regionstockholm.se
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A 2-arm (sequence), 2-period, 2-treatments, single blinded (outcome assessor), randomized crossover-trial (12+12 weeks with immediate contrast) comparing a low-carbohydrate-high-fat diet (LCHF) with a high-carbohydrate-low-fat diet (HCLF) among individuals with prodromal Alzheimer's disease.


Description:

The impact of macronutritional composition on cognitive health is not fully understood. On one hand, the World Health Organization (WHO) guidelines propose a limit of total fat intake at 30% of total energy intake (E%), implying that carbohydrates provide at least 50 E%. On the other hand, some pilot studies on ketogenic diets (strict carbohydrate restriction, ≤10 E%) have shown promising results-while liberal carbohydrate restriction has not been investigated in a clinical trial among individuals with Alzheimer's disease or mild cognitive impairment (MCI). It is unclear how important the metabolic state ketosis is for driving potential effects of ketogenic diets on cognitive health outcomes, and our previous observational analyses suggest that even macronutritional changes in the non-ketogenic range might impact cognitive function-although estimated effects differed between sub-samples. This pilot study evaluates the potential of liberal carbohydrate restriction, alternatively fat restriction, as targets for future large scale trials. Participants must be diagnosed with prodromal Alzheimer's disease, which means MCI in combination with biologically validated Alzheimer-pathology-but absence of dementia. The aim of this trial is to generate a contrast within participants regarding a diet parameter of special interest: the carbohydrate/fat-ratio (CFr). In a randomized order, participants will be exposed to 12 weeks with a low CFr diet (LCHF) and 12 weeks with a high CFr diet (HCLF). In LCHF, sustained ketosis is not an aim but transient mild ketosis may appear in some participants. The following strategies will be used to enhance adherence: - A mandatory supportive study partner. - Delivery of one daily meal. - Delivery of some key ingredients for self-prepared meals. - Individualized guidance by a dietitian, with consideration of preferred protein sources and complexity of cooking. Beyond a dichotomized comparison between the diet phases, the study is expected to generate data for a substantial number of observational panel analyses where individual continuous CFr-levels assessed at 5 timepoints may be used as the predictor variable. Those CFr-data will be assessed in parallel with health outcomes including neurodegenerative biomarkers in blood, metabolic biomarkers, and Continous Glucose Monitoring (CGM). Cognitive performance is measured only at 3 timepoints to minimize learning effects. The sample size is adapted to assess feasibility and trends in health outcomes. Due to the limited statistical power there is a considerable risk for type-II errors; therefore, p-values >0.05 should not be interpreted as absence of a clinically meaningful effect in this pilot. Effect modification will be explored by one pre-specified stratification: 1. Apolipoprotein E (APOE) genotypes epsilon-3/4 and 4/4; 2. All other APOE-genotypes. A cross-over design with immediate contrast (no "wash-out" period) is applied, since it is not possible to define a wash-out value of CFr or reliably keep all participants on a particular CFr between the diet periods. Period 1 (and 2) may have a carry-over effect from pre-study CFr and period 2 may have a carry-over effect from period 1. Primary comparisons against baseline are at the end of each period (weeks 12 & 24) when carry-over effects are assumed to be relatively low.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date April 2026
Est. primary completion date October 2025
Accepts healthy volunteers No
Gender All
Age group 50 Years to 85 Years
Eligibility Inclusion Criteria: - Ability to fully understand written and verbal information regarding the study and provide signed and dated informed consent - Prodromal Alzheimer's disease, as defined by Mild Neurocognitive Disorder due to Alzheimer's disease (AD) according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria, and evidence for underlying AD pathology by either: - Cerebrospinal fluid (CSF) ß-amyloid 1-42/1-40x10 ratio < 1 and/or total tau and/or phospho-tau and/or ß-amyloid 42 based on local cut-offs OR - Magnetic Resonance Imaging (MRI) evidence for medial temporal lobe atrophy (MTA score 1 or higher [mesiotemporal atrophy]) OR - Abnormal Fludeoxyglucose F18 (FDG) Positron Imaging Tomography (PET) and/or Pittsburgh Compound-B (PiB) PET compatible with AD type changes. (When the diagnosis prodromal AD is confirmed from medical record, no cognitive testing or renewed assessment of biological AD-pathology is needed for fulfilling this criterion.) - Montreal Cognitive Assessment (MoCa) =20. - Availability of a study partner with sufficient contact with the participant, willing and able to give follow-up information on the participant as well as supporting the participant throughout the study. - Self-reported expected motivation and ability to prepare most weakly meals according to given instructions, with support from the study partner. - Accept plant-based food, plus food from at least one of the following categories: A. Fish; B. Meat; C. Eggs and dairy - Ability to reliably undergo a cognitive test in Swedish Exclusion Criteria: - Major Neurocognitive Disorder (dementia) according to DSM-5 - Body-mass Index (BMI) < 18 or BMI > 35 - Diagnosed Diabetes Mellitus. - Ongoing treatment with Metformin, Glucagon-Like Peptide 1 (GLP-1)-analog, or Sodium-Glucose Transport Protein 2 (SGLT-2)-inhibitors - Diagnosed Familial Hypercholesterolemia - Untreated or unstable Hypertension - Alcohol or Substance abuse (current or within 2 years) - A concomitant serious disease (e.g., cancer, or major psychiatric disorder or other neurological disorder than AD) as judged by study physician - Major depression or Suicidal ideations (current or within 2 years) - History of Stroke or Myocardial infarction during the last 5 years. - Subjects with brain MRI (or CT) scan clinically significant infarct, intracranial macro bleeding, mass lesion or Normal Pressure Hydrocephalus. Those subjects with an MRI scan demonstrating minimal white matter changes (Fazekas scale for white matter lesions classification of 2 or below) and up to 2 lacunar infarcts which are judged to be clinically insignificant are allowed. - Severe loss of vision or communicative ability - Conditions preventing cooperation as judged by the study physician. - Participation in any other intervention trial within 30 days (or, if applicable, 5 half-lives of the relevant drug if longer) before baseline and along the study period. - Any planned changes in cognitive enhancers (e.g., ginkgo, cholinesterase inhibitors), statins, antidepressants, sleeping pills, supplements like medium-chain triglycerides, or any medication expected to influence cognitive function. Such medications are accepted if taken on a stable dose =3 months prior to baseline assessment and should, if possible, remain on the same dose during the study. Unplanned changes that take place within the study do not imply exclusion but should be registered in the case report form (CRF). - Deviations from habitual diet within 1 month before study start. A carbohydrate-restricted or fat-restricted diet, as well as any time-restricted eating, is accepted as habitual diet if stable (and the participant is open to change).

Study Design


Intervention

Other:
LCHF
A diet intervention with the following macronutrient targets: Carbohydrates: 10-25 E%; Fat 50-70 E%; Protein: 20-25 E%; Alcohol 0-5 E%
HCLF
A diet intervention with the following macronutrient targets: Carbohydrates: 50-60 E%; Fat 25-30 E%; Protein: 15-20 E%; Alcohol 0-5 E%

Locations

Country Name City State
Sweden Karolinska University Hospital Solna

Sponsors (4)

Lead Sponsor Collaborator
Karolinska University Hospital af Jochnick Foundation, Fingers Brain Health Institute, Karolinska Institutet

Country where clinical trial is conducted

Sweden, 

References & Publications (2)

Norgren J, Sindi S, Matton A, Kivipelto M, Kareholt I. APOE-Genotype and Insulin Modulate Estimated Effect of Dietary Macronutrients on Cognitive Performance: Panel Analyses in Nondiabetic Older Adults at Risk of Dementia. J Nutr. 2023 Sep 29:S0022-3166(23)72611-4. doi: 10.1016/j.tjnut.2023.09.016. Online ahead of print. — View Citation

Norgren J, Sindi S, Sandebring-Matton A, Ngandu T, Kivipelto M, Kareholt I. The Dietary Carbohydrate/Fat-Ratio and Cognitive Performance: Panel Analyses in Older Adults at Risk for Dementia. Curr Dev Nutr. 2023 May 7;7(6):100096. doi: 10.1016/j.cdnut.2023.100096. eCollection 2023 Jun. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Continuous Glucose Monitoring (CGM) Concentrations of blood glucose measured in blinded mode for participants every 5th minute. Week 0, 6, 12, 18, 24; Seven days at each timepoint.
Other Food Record Nutrient intake from self-reported 7-day food record. Week 0, 6, 12, 18, 24
Other Body-Mass Index (BMI) Calculated from measures of weight and height (kg/m^2). Week 0, 6, 12, 18, 24
Other Waist (cm) Week 0, 6, 12, 18, 24
Other Blood Pressure Systolic and diastolic blood pressure. Week 0, 6, 12, 18, 24
Other Ketone Bodies in Blood Capillary concentrations of ß-hydroxybutyrate (BHB) measured with a handheld meter after an overnight fasting. Week 0, 6, 12, 18, 24
Other Glucose Blood concentrations of glucose after an overnight fasting. Week 0, 6, 12, 18, 24
Other Glucose in Oral Glucose Tolerance Test (OGTT) Blood concentrations of glucose after 75 g glucose load. Week 0, 12, 24; (Minutes 0, 30, & 120)
Other Insulin (OGTT) Blood concentrations of insulin after 75 g glucose load. Week 0, 12, 24; (Minutes 0, 30, & 120)
Other C-Peptide (OGTT) Blood concentrations of C-Peptide after 75 g glucose load. Week 0, 12, 24; (Minutes 0, 30, & 120)
Other Lactate (OGTT) Blood concentrations of Lactate after 75 g glucose load. Week 0, 12, 24; (Minutes 0, 30, & 120)
Other Hemoglobin 1Ac (HbA1c) Blood concentrations of glycated hemoglobin Week 0, 12, 24
Other Apolipoprotein B (ApoB) Blood concentrations of ApoB Week 0, 12, 24
Other High-Density Lipoprotein Cholesterol (HDL-C) Blood concentrations of HDL-C Week 0, 12, 24
Other Triglycerides Blood concentrations of Triglycerides Week 0, 12, 24
Other Lipoprotein(a) Blood concentrations of Lipoprotein(a) Week 0, 12, 24
Other The Montreal Cognitive Assessment (MoCa) (Score 0-30; higher=better) Week 0, 12, 24
Other Cognitive Sub-domain: Memory Mean z-scores of cognitive sub-tests 1-5, 7, 9-10, as defined above. Week 0, 12, 24
Other Cognitive Sub-domain: Non-Memory (Executive function / Processing speed) Mean z-scores of cognitive sub-tests 6, 8, 11-13, as defined above. Week 0, 12, 24
Other Geriatric Depression Scale (GDS-15) Scale 0-15; higher score indicate more depressive symptoms. Week 0, 12, 24
Other RAND-36 Health-related quality of life (HRQoL) questionnaire from RAND Corporation; higher score=better. Week 0, 12, 24
Other Subjective Experiences of Diets Questionnaires specific for this study, assessing subjective experiences by the participant and the study partner respectively. Week 12, 24
Other Adverse Events According to International Council for Harmonisation and (ICH) - Good Clinical Practice (GCP) standards. Through study completion (typically 24 weeks)
Primary Recruitment Rate Number of participants that are randomized within 1 year from start of recruitment, or time to reach 40 randomized participants if reached within <1 year. 1 year from recruitment start
Primary Adherence Self-reported carbohydrate/fat-ratio (CFr) from 7-day food record:
Intra-individual difference in CFr (log-transformed) between the diet treatments (mean Period 1 [week 6 &12] vs. mean Period 2 [week 18 & 24], reversed by arm) expressed as standard deviations of the baseline distribution.
Week 0, 6, 12, 18, 24
Primary Retention Rate The proportion of those randomized who complete the 12-week and 24-week follow-up with data on both a. Self-reported carbohydrate/fat-ratio; b. Secondary outcomes Until the end of data collection
Secondary Global Cognition Mean of z-scores (higher=better) from 13 sub-tests of a modified Neuropsychological Test Battery (NTB), subsequently z-transformed. Sources of sub-tests include Consortium to Establish a Registry for Alzheimer's Disease (CERAD) test battery and Wechsler Memory Scale (WMS).
CERAD 10-word List Learning
CERAD 10-word Delayed Recall
CERAD 10-word Recognition
WMS-Verbal Immediate (story)
WMS-Verbal Delayed (story)
WMS-Digit Span
WMS-Visual Paired Associates
Category Fluency
CERAD Constructional Praxis
CERAD Constructional Praxis Recall
Letter Digit Substitution Test
Trail Making Test A
Trail Making Test B
Week 0, 12, 24
Secondary Amyloid ß-42/40 Ratio between ß-Amyloid concentrations in blood. Week 0, 6, 12, 18, 24; Primary comparison: ?0-12 weeks (w) vs. ?0-24 w, reversed by arm.
Secondary Phospho-Tau (pTau) 181/231/217 pTau concentrations in blood. Week 0, 6, 12, 18, 24; Primary comparison: ?0-12 w vs. ?0-24 w, reversed by arm.
Secondary Neurofilament Light (NFL) NFL concentrations in blood. Week 0, 6, 12, 18, 24; Primary comparison: ?0-12 w vs. ?0-24 w, reversed by arm.
Secondary Glial Fibrillary Acidic Protein (GFAP) GFAP concentrations in blood. Week 0, 6, 12, 18, 24; Primary comparison: ?0-12 w vs. ?0-24 w, reversed by arm.
See also
  Status Clinical Trial Phase
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A